Literature DB >> 17484812

The endovascular management of intracranial vascular disease including the MERCI device.

Chirag D Gandhi1, David M Johnson, Aman B Patel.   

Abstract

The prompt and aggressive management of acute stroke has become the standard of care as public awareness and the available successful treatment options both increase. The intravenous administration of tissue plasminogen activator within an established treatment window has been determined through large well-designed studies. The endovascular strategies for acute stroke have evolved significantly over the past 5 years and have been prompted by the limits of the intravenous treatment, as well as by the desire to demonstrate improved recanalization rates and improved long-term outcomes. Among these interventional treatment options are the intra-arterial administration of tissue plasminogen activator and newer antiplatelet agents, mechanical thrombectomy with the MERCI device, and intracranial angioplasty and stenting. This article outlines the major studies that have defined the current field of acute stroke management and discusses the basic treatment paradigms that are commonly used today.

Entities:  

Year:  2007        PMID: 17484812     DOI: 10.1007/s11936-007-0003-8

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  37 in total

1.  Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis.

Authors:  Shinichi Nakano; Tsutomu Iseda; Takumi Yoneyama; Hirokazu Kawano; Shinichiro Wakisaka
Journal:  Stroke       Date:  2002-12       Impact factor: 7.914

2.  Abciximab in acute ischemic stroke. A randomized, double-blind, placebo-controlled, dose-escalation study.

Authors: 
Journal:  Stroke       Date:  2000-03       Impact factor: 7.914

Review 3.  Hyperacute imaging of ischemic stroke: role in therapeutic management.

Authors:  Scott L Selco; David S Liebeskind
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

4.  Is the benefit of early recanalization sustained at 3 months? A prospective cohort study.

Authors:  Lise A Labiche; Fahmi Al-Senani; Anne W Wojner; James C Grotta; Marc Malkoff; Andrei V Alexandrov
Journal:  Stroke       Date:  2003-02-13       Impact factor: 7.914

5.  Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight.

Authors:  E C Haley; C Lewandowski; B C Tilley
Journal:  Ann Emerg Med       Date:  1997-11       Impact factor: 5.721

Review 6.  Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis.

Authors:  P D Schellinger; J B Fiebach; A Mohr; P A Ringleb; O Jansen; W Hacke
Journal:  Crit Care Med       Date:  2001-09       Impact factor: 7.598

7.  Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.

Authors:  Marta Rubiera; José Alvarez-Sabín; Marc Ribo; Joan Montaner; Esteban Santamarina; Juan F Arenillas; Rafael Huertas; Pilar Delgado; Francisco Purroy; Carlos A Molina
Journal:  Stroke       Date:  2005-06-09       Impact factor: 7.914

8.  Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.

Authors:  Dong Joon Kim; Dong Ik Kim; Seo Hyun Kim; Kyung Yeol Lee; Ji Hoe Heo; Sang Won Han
Journal:  Neuroradiology       Date:  2005-06-28       Impact factor: 2.804

9.  Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy.

Authors:  S R Kapadia; C T Bajzer; K M Ziada; D L Bhatt; O M Wazni; M J Silver; E G Beven; K Ouriel; J S Yadav
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

10.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

View more
  2 in total

1.  Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor.

Authors:  Shahid M Nimjee; Jens D Lohrmann; Haichen Wang; David J Snyder; Thomas J Cummings; Richard C Becker; Sabah Oney; Bruce A Sullenger
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

2.  Vertebrobasilar recanalization after 12 h of onset using balloon expandable stent and thrombolysis.

Authors:  Alfredo Casasco; Hugo Cuellar; Francisco Gilo; Leopoldo Guimaraens; Jacques Theron
Journal:  Emerg Radiol       Date:  2007-09-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.